UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 570

Sortiert nach

Epidemiology and Risk Factors of Urothelial Bladder Cancer

European urology, 2013-02, Vol.63 (2), p.234-241

2013

Volltextzugriff (PDF)

Photodynamic Diagnosis of Non–muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data

European urology, 2013-11, Vol.64 (5), p.846-854

2013

Volltextzugriff (PDF)

Evaluation of Genetic Variants in MicroRNA-Related Genes and Risk of Bladder Cancer

Cancer research (Chicago, Ill.), 2008-04, Vol.68 (7), p.2530-2537

2008

Volltextzugriff (PDF)

Urine Markers for Detection and Surveillance of Non–Muscle-Invasive Bladder Cancer

European urology, 2011-09, Vol.60 (3), p.484-492

2011

Volltextzugriff (PDF)

Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy

The Journal of urology, 2012-07, Vol.188 (1), p.58-62

2012

Volltextzugriff (PDF)

Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin

European urology, 2016-02, Vol.69 (2), p.197-200

2016

Volltextzugriff (PDF)

Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center

European urology, 2013-08, Vol.64 (2), p.307-313

2013

Volltextzugriff (PDF)

Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancer

World journal of urology, 2019-01, Vol.37 (1), p.3-13

2019

Volltextzugriff (PDF)

Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy

The Journal of urology, 2014-01, Vol.191 (1), p.40-47

2014

Volltextzugriff (PDF)

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer

Cell reports (Cambridge), 2019-05, Vol.27 (6), p.1781-1793.e4

2019

Volltextzugriff (PDF)

Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer

Journal of clinical oncology, 2009-06, Vol.27 (16), p.2592-2597

2009

Volltextzugriff (PDF)

Detection of bladder cancer using a point-of-care proteomic assay

JAMA : the journal of the American Medical Association, 2005-02, Vol.293 (7), p.810

2005

Volltextzugriff (PDF)

Surveillance for recurrent bladder cancer using a point-of-care proteomic assay

JAMA : the journal of the American Medical Association, 2006-01, Vol.295 (3), p.299

2006

Volltextzugriff (PDF)

Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma

Cancer, 2010-07, Vol.116 (13), p.3127-3134

2010

Volltextzugriff (PDF)

Clinical model of lifetime cost of treating bladder cancer and associated complications

Urology (Ridgewood, N.J.), 2006-09, Vol.68 (3), p.549-553

2006

Volltextzugriff (PDF)

The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non‐muscle‐invasive bladder cancer treated with bacillus Calmette–Guérin

BJU international, 2021-07, Vol.128 (1), p.65-71

2021

Volltextzugriff (PDF)

Lymph Node Density Is Superior to TNM Nodal Status in Predicting Disease-Specific Survival After Radical Cystectomy for Bladder Cancer: Analysis of Pooled Data From MDACC and MSKCC

Journal of clinical oncology, 2008-01, Vol.26 (1), p.121-126

2008

Volltextzugriff (PDF)

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers

Clinical chemistry (Baltimore, Md.), 2010-06, Vol.56 (6), p.e1-e48

2010

Volltextzugriff (PDF)

Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer

The Journal of urology, 2013-09, Vol.190 (3), p.850-856

2013

Volltextzugriff (PDF)

Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710)

BJU international, 2011-09, Vol.108 (5), p.693-699

2011

Volltextzugriff (PDF)

Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells

Clinical cancer research, 2011-05, Vol.17 (9), p.2863-2873

2011

Volltextzugriff (PDF)

Surgical Factors Influence Bladder Cancer Outcomes: A Cooperative Group Report

Journal of clinical oncology, 2004-07, Vol.22 (14), p.2781-2789

2004

Volltextzugriff (PDF)

Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial

The Journal of urology, 2012-03, Vol.187 (3), p.862-867

2012

Volltextzugriff (PDF)

Novel fluorescence in situ hybridization‐based definition of bacille Calmette‐Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies

BJU international, 2016-05, Vol.117 (5), p.754-760

2016

Volltextzugriff (PDF)

A Phase 2 Clinical Trial of Sequential Neoadjuvant Chemotherapy With Ifosfamide, Doxorubicin, and Gemcitabine Followed by Cisplatin, Gemcitabine, and Ifosfamide in Locally Advanced Urothelial Cancer: Final Results

Cancer, 2013-02, Vol.119 (3), p.540-547

2013

Volltextzugriff (PDF)

1 – 25 von 570

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(546)
Mit Volltextzugriff
(352)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(308)
Science & Technology
(305)
Life Sciences & Biomedicine
(304)
Biological And Medical Sciences
(237)
Medical Sciences
(229)
Male
(185)
Urology & Nephrology
(171)
Nephrology. Urinary Tract Diseases
(170)
Tumors Of The Urinary System
(147)
Female
(141)
Middle Aged
(139)
Urinary Tract. Prostate Gland
(139)
Aged
(126)
Oncology
(121)
Urinary Bladder Neoplasms - Pathology
(108)
Bladder Cancer
(102)
Urology
(102)
Tumors
(72)
Urinary Bladder Neoplasms - Genetics
(66)
Adult
(62)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The Journal Of Urology
(183)
Urologic Oncology
(54)
Urology
(53)
Cancer
(25)
The journal Of Urology/the journal Of Urology
(23)
European Urology
(18)
Journal Of Clinical Oncology
(18)
Cancer Research
(16)
Journal Of Urology
(14)
Bju International
(13)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Epidemiology and Risk Factors of Urothelial Bladder Cancer

Photodynamic Diagnosis of Non–muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data

Evaluation of Genetic Variants in MicroRNA-Related Genes and Risk of Bladder Cancer

Urine Markers for Detection and Surveillance of Non–Muscle-Invasive Bladder Cancer

Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy

Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin

Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center

Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancer

Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer

Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer

Detection of bladder cancer using a point-of-care proteomic assay

Surveillance for recurrent bladder cancer using a point-of-care proteomic assay

Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma

Clinical model of lifetime cost of treating bladder cancer and associated complications

The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non‐muscle‐invasive bladder cancer treated with bacillus Calmette–Guérin

Lymph Node Density Is Superior to TNM Nodal Status in Predicting Disease-Specific Survival After Radical Cystectomy for Bladder Cancer: Analysis of Pooled Data From MDACC and MSKCC

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers

Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer

Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710)

Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells

Surgical Factors Influence Bladder Cancer Outcomes: A Cooperative Group Report

Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial

Novel fluorescence in situ hybridization‐based definition of bacille Calmette‐Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies

A Phase 2 Clinical Trial of Sequential Neoadjuvant Chemotherapy With Ifosfamide, Doxorubicin, and Gemcitabine Followed by Cisplatin, Gemcitabine, and Ifosfamide in Locally Advanced Urothelial Cancer: Final Results

Suchergebnisse filtern